SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Set your goals is shown using the collage with aim and the hand. Business targeting, aiming, focus concept and way to achieve a goal
Ovarian cancer
Corcept’s Ovarian Cancer Drug Hits ‘Robust’ Efficacy in Phase III, Setting Up Challenge to Merck, AbbVie
Corcept’s overall survival data “look competitive” with AbbVie’s Elahere and Merck’s blockbuster Keytruda, Truist Securities said Thursday.
January 26, 2026
 · 
2 min read
 · 
Tristan Manalac
Two hands locked in a handshake cut by a pair of scissors, symbolizing a severed relationship or partnership. Black and white collage illustration on paper textured background
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
 · 
1 min read
 · 
Tristan Manalac
RED pawn beating competition over white background. Standing out from the crowd. Business strategy, outsider becoming the leader.3D rendering on white background.
Rare diseases
Rare Disease Biotechs Stand To Lose $4B if Priority Voucher Program Not Reinstated: Report
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
January 26, 2026
 · 
7 min read
 · 
Heather McKenzie
Metaverse avatars of sandboxes games in virtual reality through VR goggles in the world of Metaverse 3D illustrations
Opinion
To Accelerate Rare Disease Progress, Take a Sandbox Approach
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
January 26, 2026
 · 
5 min read
 · 
Oxana Iliach
Brain neurons synapse in human head isolated on black background, 3D rendering.
Parkinson’s disease
5 Investigational Therapies That Could Change the Parkinson’s Landscape
From opening new therapeutic mechanisms to repairing neuronal damage, investigational molecules from Ventyx Therapeutics, AC Immune, Gain Therapeutics and more could shape the future of Parkinson’s disease treatment.
January 26, 2026
 · 
9 min read
 · 
Tristan Manalac
Pros and cons collage. Mixed media thumbs up and thumbs down hand gestures with speech bubbles. Review concept, positive and negative feedback vector illustration.
Immunology and inflammation
Sanofi Stumbles Again in Eczema—But Plans FDA Filing for OX40 Blocker Anyway
The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink Partners said “fell well below expectations.”
January 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Capitol in Washington
Government
Spending Bill Clears House, Keeping Priority Review Voucher Hopes Alive
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
January 23, 2026
 · 
3 min read
 · 
Tristan Manalac
Government red tape concept and American bureaucracy symbol as an icon of the flag of the United States with the red stripes getting tangled in confusion as a metaphor for political and administration inefficiency.
Rare diseases
Rare Disease Vouchers Caught in Political Abyss. It Didn’t Have To Be This Way
The FDA’s rare pediatric disease priority review voucher program missed reauthorization at the last minute in 2024; advocates have been fighting to get it back ever since.
January 23, 2026
 · 
3 min read
 · 
Heather McKenzie
Concept art showing a money icon and human hands
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
January 23, 2026
 · 
1 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS